Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015
Single-center experience in Europe illustrates safe control of hepatic metastases with the Delcath Hepatic CHEMOSAT Delivery System
NEW YORK, May 29, 2015 -- Delcath Systems, Inc. (DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015. The abstract is titled, "Single Centre Experience of Chemosaturation Percutaneous Hepatic Perfusion in the Treatment of Metastatic Uveal Melanoma" and can be accessed here.
- Published: 29 May 2015
- Written by Editor
- Hits: 30